<DOC>
	<DOCNO>NCT02060370</DOCNO>
	<brief_summary>The goal clinical research study learn safety give sunitinib patient metastatic kidney cancer 2 week follow 1 week receive drug . Researchers want learn side effect drug effect different dose schedule .</brief_summary>
	<brief_title>Sunitinib Scheduling Metastatic Renal Cell Carcinoma ( mRCC )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , take sunitinib capsule mouth every day 2 week , follow 1 week receive study drug . This repeat every 3 week . Every 6 week 1 study cycle . If side effect tell study doctor right away . The study doctor may change dose study drug . Study Visits : Every day first week , least 1 time week study , blood pressure check ( either home , clinic , local doctor ) . You need write blood pressure blood pressure diary time check bring diary clinic visit . On Day 1 Cycle 1 : - You physical exam . - Blood ( 3-4 tablespoon ) draw routine biomarker test . - You fill questionnaire quality life feeling . This take 5 minute . On Day 42 every cycle : - You physical exam . - Blood ( 3-4 tablespoon ) draw routine test . On Day 42 every even-numbered cycle ( Cycles 2 , 4 , 6 , ) : - You CT scan chest , abdomen , pelvis . - Blood ( 1 tablespoon ) drawn check thyroid function . - Blood ( 2 tablespoon ) draw biomarker testing . ( Cycles 2 , 4 , 6 ) - You fill questionnaire quality life feeling . ( Cycles 2 , 4 , 6 ) At time doctor think need , additional blood ( 1 tablespoon ) may draw check thyroid function , may need bone scan CT scan MRI brain check status disease . Length Study : You may continue take study drug long study doctor think best interest . You take treatment disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . However , study team may perform medical record review follow-up call check . If call , last 5-10 minute . End-of-Treatment Visit : After long receive study drug , end-of-treatment visit . You physical exam blood ( 3-4 tablespoon ) draw routine biomarker test . End-of- Treatment Follow-Up Visit : About 30 day end-of-treatment visit follow-up visit follow procedure perform : - You physical exam . - Blood ( 3-4 tablespoon ) draw routine test . - You CT scan chest , abdomen pelvis check status disease . This investigational study . Sunitinib FDA approve commercially available treat advance kidney cancer . The dosing schedule use study investigational . Up 60 participant enrol study . Up 60 may take part MD Anderson .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Histologically cytologicallyconfirmed metastatic renal cell carcinoma clear cell histology . Prior nephrectomy requirement eligibility 2 . Age &gt; /=18 year 3 . Measurable evaluable metastatic disease per RECIST v 1 4 . ECOG performance status 01 5 . Normal organ bone marrow function define : Serum aspartate transaminase ( AST ) serum glutamic oxaloacetic transaminase ( SGOT ) serum alanine transaminase ( ALT ) serum glutamic pyruvic transaminase ( SGPT ) &lt; /= 2.5 x laboratory upper limit normal ( ULN ) ; Total serum bilirubin &lt; /= 2.0 x ULN ; Absolute neutrophil count ( ANC ) &gt; /= 1500/µL ; Platelets &gt; /= 100,000/µL ; Hemoglobin &gt; /= 9.0 g/dL ( transfusion permit ) ; Serum calcium &lt; /= 12.0 mg/dL ; Serum creatinine &lt; /= 2.5 mg/dL 6 . Patients history deep venous thromboembolism pulmonary embolism treatment anticoagulation eligible study . 7 . Subjects must ability understand willingness sign write informed consent document 1 . Prior treatment sunitinib systemic therapy metastatic setting ( prior neo/adjuvant therapy allow complete &gt; 6 month prior registration therapy discontinue toxicity ) 2 . Uncontrolled hypertension ( define blood pressure &gt; 140/90 mm Hg control antihypertensive ) 3 . Prior intraabdominal , intrathoracic , vascular , spinal intracranial surgery radiation therapy within 4 week start treatment 4 . History known brain metastasis , spinal cord compression , carcinomatous meningitis 5 . New York Heart Association ( NYHA ) grade II great congestive heart failure 6 . Current treatment another therapeutic clinical trial 7 . Any follow within precede 6 month myocardial infarction , severe/unstable angina , severe peripheral vascular disease ( claudication ) procedure peripheral vasculature , coronary/peripheral artery bypass , graft , cerebrovascular accident transient ischemic attack , clinically significant bleed 8 . Pregnant breastfeed woman exclude study unknown , potential risk adverse event nurse infant secondary treatment mother sunitinib . Breastfeeding must discontinue mother treated sunitinib 9 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness 10 . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction sunitinib . In addition , patient increase risk lethal infection treat marrow suppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Genitourinary Cancer</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>mRCC</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Sunitinib malate</keyword>
	<keyword>SUO11248</keyword>
	<keyword>Sutent</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
</DOC>